Cargando…

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

Diabetes mellitus (DM) is a major metabolic disorder currently affecting over 200 million people worldwide. Approximately 90% of all diabetic patients suffer from Type 2 diabetes mellitus (T2DM). The world's economy coughs out billions of dollars annually to diagnose, treat and manage patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lotfy, Mohamed, Singh, Jaipaul, Kalász, Huba, Tekes, Kornelia, Adeghate, Ernest
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174521/ https://www.ncbi.nlm.nih.gov/pubmed/21966329 http://dx.doi.org/10.2174/1874104501105010082

Ejemplares similares

Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators
por: Adeghate, Ernest, et al.
Publicado: (2011)

Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2014)

Medicinal Chemistry of the Anti-Diabetic Effects of Momordica Charantia: Active Constituents and Modes of Actions
por: Singh, Jaipaul, et al.
Publicado: (2011)

Amylin Analogues in the Treatment of Diabetes Mellitus: Medicinal Chemistry and Structural Basis of its Function
por: Adeghate, Ernest, et al.
Publicado: (2011)

An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus
por: Mahgoub, Mohamed Omer, et al.
Publicado: (2023)

Pharmacognostical Sources of Popular Medicine To Treat Alzheimer’s Disease
por: Kalász, Huba, et al.
Publicado: (2018)

Pharmacokinetics of Two Chlorine-Substituted Bis-Pyridinium Mono-Aldoximes with Regenerating Effect on Butyrylcholinesterase
por: Kalász, Huba, et al.
Publicado: (2020)

Nociceptin Increases Antioxidant Expression in the Kidney, Liver and Brain of Diabetic Rats
por: Adeghate, Ernest, et al.
Publicado: (2021)

Monitoring the Level of (14)C-Labelled Selegiline Following Oral Administration
por: Kalász, Huba, et al.
Publicado: (2017)

Effects on Sperms’ Quality of Selegiline in Aged Rats
por: Kalász, Huba, et al.
Publicado: (2017)

Penetration of polar organic compounds through the blood-brain barrier
por: Kalász, Huba, et al.
Publicado: (2011)

Chronic Experimental Diabetes Accelerates Urinary Elimination of Deprenyl and its Metabolites
por: Adeghate, Ernest, et al.
Publicado: (2008)

Efficacy of N-Acetylcysteine, Glutathione, and Ascorbic Acid in Acute Toxicity of Paraoxon to Wistar Rats: Survival Study
por: Nurulain, Syed M., et al.
Publicado: (2015)

Medicinal Chemistry of Novel Anti-Diabetic Drugs
por: Adeghate, Ernest
Publicado: (2011)

Early (5-Day) Onset of Diabetes Mellitus Causes Degeneration of Photoreceptor Cells, Overexpression of Incretins, and Increased Cellular Bioenergetics in Rat Retina
por: Adeghate, Jennifer O., et al.
Publicado: (2021)

Monitoring by HPLC of Chamomile Flavonoids Exposed to Rat Liver Microsomal Metabolism
por: Petroianu, Georg, et al.
Publicado: (2009)

Mechanisms of COVID-19-induced heart failure: a short review
por: Adeghate, Ernest A., et al.
Publicado: (2020)

Adropin’s Role in Energy Homeostasis and Metabolic Disorders
por: Ali, Ifrah Ismail, et al.
Publicado: (2022)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
por: Chhabria, Srishti, et al.
Publicado: (2022)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function
por: Gong, Quan, et al.
Publicado: (2015)

Basic Aspects of the Pharmacodynamics of Tolperisone, A Widely Applicable Centrally Acting Muscle Relaxant
por: Tekes, Kornelia
Publicado: (2014)

Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus
por: Yaribeygi, Habib, et al.
Publicado: (2021)

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
por: Zhang, Zeqing, et al.
Publicado: (2017)

Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus
por: Pilszyk, Aleksandra, et al.
Publicado: (2022)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Incretin - based therapy in diabetes mellitus: present scenario and expanding horizons
por: Kohli, Suresh Chandra
Publicado: (2016)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Thiazolidinediones: An In–Depth Study of Their Synthesis and Application to Medicinal Chemistry in the Treatment of Diabetes Mellitus
por: Long, Nathan, et al.
Publicado: (2021)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
por: Yu, Sung Hoon, et al.
Publicado: (2011)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz, Stanley, et al.
Publicado: (2010)

Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
por: Nisal, Kaustubh, et al.
Publicado: (2012)

Potentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
por: Groeneveld, Onno N, et al.
Publicado: (2015)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
por: Thomas, Merlin C., et al.
Publicado: (2016)

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Wang, Qixian, et al.
Publicado: (2018)

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
por: Yu, Dong-Ni, et al.
Publicado: (2020)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6riftg8vmev4edi877h4n8he8q